Using a commercial anti-HLA-F mAb EPR6803 (Abcam, Cambridge, UK), the expression of HLA-F was investigated in nasopharyngeal carcinoma [24] and brain glioma [25]. This evidence concerns the gene HLA-F and nasopharyngeal carcinoma.